{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:15Z","timestamp":1707524175514},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,22]]},"DOI":"10.7759\/cureus.13488","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T16:38:31Z","timestamp":1614011911000},"source":"Crossref","is-referenced-by-count":0,"title":["Transient Ischemic Attack and Hypoventilation 12 Hours After Intra-vitreal Aflibercept Injection"],"prefix":"10.7759","author":[{"given":"Tariq","family":"Hamadneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Akkawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MeiXia","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Yamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Azamtta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"2019-2020 Basic and Clinical Science Course, Section 2: Fundamentals and Principles of Ophthalmology","year":"2019","unstructured":"2019-2020 Basic and Clinical Science Course, Section 2. Fundamentals and Principles of Ophthalmology. Vikram S. Brar (ed): American Academy of Ophthalmology, San Francisco, United States; 2019. 12:475."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-008-0675-8","article-title":"VEGF inhibition: insights from preclinical and clinical studies","volume":"335","author":"Crawford Y","year":"2009","unstructured":"Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335:261-9. 10.1007\/s00441-008-0675-8","journal-title":"Cell Tissue Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara N","year":"2006","unstructured":"Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006, 26:859-70. 10.1097\/01.iae.0000242842.14624.e7","journal-title":"Retina"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik JF","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al.. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014, 121:2247-54. 10.1016\/j.ophtha.2014.05.006","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al.. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015, 372:1193-203. 10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903418422","article-title":"Clinical safety of ranibizumab in age-related macular degeneration","volume":"9","author":"Schmidt-Erfurth U","year":"2010","unstructured":"Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf. 2010, 9:149-65. 10.1517\/14740330903418422","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.040","article-title":"Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?","volume":"152","author":"Lim LS","year":"2011","unstructured":"Lim LS, Cheung CMG, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?. Am J Ophthalmol. 2011, 152:329-331. 10.1016\/j.ajo.2011.05.040","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.178574","article-title":"Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review","volume":"95","author":"Schmucker C","year":"2011","unstructured":"Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011, 95:308-17. 10.1136\/bjo.2009.178574","journal-title":"Br J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos N","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al.. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012, 15:171-85. 10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara N","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004, 3:391-400. 10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2012.48.5.1805931","article-title":"Aflibercept for the treatment of neovascular age-related macular degeneration","volume":"48","author":"Verner-Cole EA","year":"2012","unstructured":"Verner-Cole EA, Davis SJ, Lauer AK. Aflibercept for the treatment of neovascular age-related macular degeneration. Drugs Today (Barc). 2012, 48:317-29. 10.1358\/dot.2012.48.5.1805931","journal-title":"Drugs Today (Barc)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery RL","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al.. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014, 98:1636-41. 10.1136\/bjophthalmol-2014-305252","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura V","year":"2010","unstructured":"Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010, 49:287-97. 10.3109\/02841860903524396","journal-title":"Acta Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci FA","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, et al.. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007, 99:1232-9. 10.1093\/jnci\/djm086","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy U","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al.. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013, 382:1258-67. 10.1016\/S0140-6736(13)61501-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","volume":"98","author":"Avery RL","year":"2014","unstructured":"Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. Br J Ophthalmol. 2014, 98:i7-10. 10.1136\/bjophthalmol-2013-303844","journal-title":"Br J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery RL","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al.. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab\t. Retina. 2017, 37:1847-1858. 10.1097\/IAE.0000000000001493","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150688","article-title":"The vascular endothelial growth factor inhibitors ranibizumab and aflibercept markedly increase expression of atherosclerosis-associated inflammatory mediators on vascular endothelial cells","volume":"11","author":"Arnott C","year":"2016","unstructured":"Arnott C, Punnia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S. The vascular endothelial growth factor inhibitors ranibizumab and aflibercept markedly increase expression of atherosclerosis-associated inflammatory mediators on vascular endothelial cells. PLoS One. 2016, 11:e0150688. 10.1371\/journal.pone.0150688","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12278","article-title":"Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and\/or direct pharmacodynamic effect?","volume":"40","author":"Thorel J","year":"2015","unstructured":"Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, Bagheri H. Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and\/or direct pharmacodynamic effect?. J Clin Pharm Ther. 2015, 40:477-9. 10.1111\/jcpt.12278","journal-title":"J Clin Pharm Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001162","article-title":"[Embolic stroke immediately after initial administration of intravitreal aflibercept]","volume":"58","author":"Mizutani H","year":"2018","unstructured":"Mizutani H, Inatomi Y, Singu T, Nakajima M, Yonehara T, Ando Y. [Embolic stroke immediately after initial administration of intravitreal aflibercept]. Rinsho Shinkeigaku. 2018, 58:314-319. 10.5692\/clinicalneurol.cn-001162","journal-title":"Rinsho Shinkeigaku"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51191-transient-ischemic-attack-and-hypoventilation-12-hours-after-intra-vitreal-aflibercept-injection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:20Z","timestamp":1707507260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51191-transient-ischemic-attack-and-hypoventilation-12-hours-after-intra-vitreal-aflibercept-injection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.13488","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}